[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582663":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":26,"responsibleParty":40,"collaborators":25,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":25,"studyType":58,"phases":59,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":69,"whyStopped":25,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Neukidney Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention","ACTIVE_COMPARATOR","QRX-3 - two capsules orally twice daily",[13],"Drug: QRX-3",{"label":15,"type":16,"description":17,"interventionNames":18},"placebo","PLACEBO_COMPARATOR","placebo pill - one capsule orally twice daily",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","QRX-3","capsule",[9,15],null,[27],{"facility":28,"status":25,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":25,"geoPoint":25,"contacts":34},"Neukidney Inc","Pasedena","Texas","77504","United States","US",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Ebima C Okundaye","CONTACT","8328316135","info@permierkidneyclinic.com",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Ebima Clifford Okundaye","President","100582663","phase-2-use-of-new-drug-qrx-3-for-prevention-and-treatment-of-chronic-kidney-disease-progression-100582663",false,"NCT06866236","Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression","Use of NAD Oxidase Modulation Agent QRX3 for Prevention and Treatment of Progressive Chronic Kidney Disease","NAD agent","Inclusion Criteria:\n\n* Inclusion criteria\n\n  * Patient with Chronic kidney disease\n  * Estimated Glomerular function by MDRD of less than 60mls\u002Fmin\n  * Patients with declining renal function ( as measured by eGFR by MDRD )\n  * Rate of decline of eGFR over the last one year of less than 20%\n  * Negative Serology markers for CKD etiology\n  * Provider perceived adherence to study follow up\n\nExclusion Criteria:\n\nRapid rate of decline in kidney function of \\> 20 % over last one year\n\n* Symptomatic renal failure\n* Presence of any suspected Acute renal failure superimposed\n* Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI\n* No known reversible cause of renal decline","ALL","18 Years","90 Years",{"count":56,"type":57},3000,"ESTIMATED","INTERVENTIONAL",[60,61],"PHASE2","PHASE3","Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.",[64,65,66],"Chronic Kidney Diseases","Acute Kidney Injury","Kidney Failure",[68],"CKD, CKD treatment , renal function","NOT_YET_RECRUITING","2025-08-31",{"date":72,"type":73},"2025-09-08","ACTUAL",{"date":75,"type":57},"2025-10",{"date":77,"type":57},"2027-07",{"name":42,"class":6},1]